CLINICAL TRIALS PROFILE FOR HISTAMINE
✉ Email this page to a colleague
All Clinical Trials for histamine
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00003991 ↗ | Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia | Completed | Maxim Pharmaceuticals | Phase 3 | 1998-07-01 | RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy. |
NCT00004316 ↗ | Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis | Completed | University of Pittsburgh | Phase 1/Phase 2 | 1995-06-01 | OBJECTIVES: I. Estimate the optimal safe dose of intravesical capsaicin in patients with interstitial cystitis. II. Evaluate the efficacy of 0.025% topical capsaicin in relieving chronic burning pain in patients with vulvar vestibulitis. III. Evaluate the effect of capsaicin on type C nerve fibers in bladder mucosa and vulvar skin. IV. Evaluate the effect of C fiber depletion on urinary levels of histamine and prostaglandin. |
NCT00004316 ↗ | Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1/Phase 2 | 1995-06-01 | OBJECTIVES: I. Estimate the optimal safe dose of intravesical capsaicin in patients with interstitial cystitis. II. Evaluate the efficacy of 0.025% topical capsaicin in relieving chronic burning pain in patients with vulvar vestibulitis. III. Evaluate the effect of capsaicin on type C nerve fibers in bladder mucosa and vulvar skin. IV. Evaluate the effect of C fiber depletion on urinary levels of histamine and prostaglandin. |
NCT00005038 ↗ | Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer | Unknown status | The Christie NHS Foundation Trust | Phase 2 | 1999-06-01 | RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Histamine dihydrochloride may prolong survival and improve quality of life in patients with metastatic kidney cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have metastatic kidney cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for histamine
Condition Name
Clinical Trial Locations for histamine
Trials by Country
Clinical Trial Progress for histamine
Clinical Trial Phase
Clinical Trial Sponsors for histamine
Sponsor Name